文献速递血管炎

巨细胞动脉炎患者报告结局与疾病活动的纵向注册研究

Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该注册队列研究纳入256例符合ACR 1990分类标准的巨细胞动脉炎患者,共1003次观察,采用线性混合效应模型评估患者报告结局与疾病活动的纵向关联。结果显示活动期与缓解期患者在RAND-12躯体成分、疼痛和整体评估上存在统计学和临床显著差异,提示选定PRO组合可作为GCA监测的辅助工具。

要点

  • 活动期与缓解期GCA患者在RAND-12躯体成分、疼痛和整体评估上差异显著。
  • RAND-12躯体成分差异为11.19(95%CI 5.67-16.71),疼痛为-12.64(95%CI -18.58至-6.70)。
  • 单一PRO不能替代正式疾病活动评估,但PRO组合可提示活动性疾病。

核心结论

  • GCA患者报告结局与疾病活动一致相关,以HRQoL躯体成分、疼痛和整体评估最为明显。
  • 活动期患者PRO评分在基线和随访期间均与缓解期患者存在统计学和临床显著差异。
  • 选定PRO组合可作为GCA监测的辅助工具,但不能替代正式疾病活动评估。

研究设计与样本

  • 基于NorVas注册的队列研究,纳入截至2024年12月12日注册且符合ACR 1990分类标准的GCA患者。
  • 纳入标准包括至少记录两次PRO且诊断时已入组,共256例患者、1003次观察,中位观察3次。
  • 采用RAND-12的躯体(PCS)和精神(MCS)复合评分及疼痛、疲劳、整体疾病评估视觉模拟量表,用线性混合效应模型分析。

主要发现

  • 所有 examined PRO在基线时活动期与缓解期之间均有显著差异。
  • 随访期间RAND-12-PCS差异为11.19(95%CI 5.67-16.71),疼痛为-12.64(95%CI -18.58至-6.70),整体评估为-9.92(95%CI -15.48至-4.35)。
  • 活动期患者PRO评分与缓解期患者的差异在基线和整个随访期间均保持统计学和临床显著。

关键数值与推荐

  • GCA分类采用ACR 1990分类标准。
  • HRQoL评估采用RAND-12,结局为躯体(PCS)和精神(MCS)复合评分。
  • 疼痛、疲劳和整体疾病评估采用视觉模拟量表。

临床怎么用

  • 在GCA随访中可结合疼痛、疲劳和患者整体评估等PRO模式提示活动性疾病并触发临床再评估。
  • RAND-12躯体成分、疼痛和整体评估对活动期与缓解期的区分较为明显,可作为监测辅助。
  • 不应以单一PRO域替代正式的疾病活动评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this registry-based cohort study was to evaluate longitudinal associations between disease activity measures and patient-reported outcomes (PROs) in GCA, and to assess whether specific PRO domains reflect clinically active disease. METHODS: Among all GCA patients registered in NorVas up to 12 December 2024, we selected patients who: (i) fulfilled the ACR 1990 classification criteria for GCA, (ii) had two PROs recorded at least once, and (iii) were included in NorVas at the time of diagnosis. HRQoL was assessed by RAND-12, using the physical (PCS) and mental (MCS) composite scores as outcomes. Visual analogue scales were used to assess pain, fatigue and global disease assessment. The association between the PROs and disease activity were evaluated using linear mixed effects models. We assessed the PROs over time and the difference in PROs between active and inactive disease. RESULTS: We included 256 patients in the study with a median of three observations each, and a total of 1003 observations. All examined PROs showed a significant difference between active and inactive disease at baseline. Statistically and clinically significant differences were retained during follow-up for RAND-12-PCS (11.19 [95% CI: 5.67, 16.71]), pain (-12.64 [95% CI: -18.58, -6.70]) and global assessment (-9.92 [95% CI: -15.48, -4.35]). CONCLUSION: Our study demonstrates a consistent association between PROs and disease activity in GCA, most pronounced for the physical component of HRQoL, pain and global assessment. Patients with active disease showed statistically and clinically significant differences in PRO scores compared with those in remission, both at baseline and throughout follow‑up. While no single PRO domain can replace formal disease activity assessment, patterns across pain, fatigue and patient global measures may signal active disease and warrant clinical reassessment. Taken together, these findings indicate that selected combinations of PROs may serve as a useful adjunct in the monitoring of GCA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Skaug HK, Fevang BS, Aßmus J, et al. Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study. Rheumatology (Oxford). 2026. PMID: 42087335. doi:10.1093/rheumatology/keag233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。